Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?

被引：96

作者：

Mannucci, Edoardo ^{[1
]}

Dicembrini, Ilaria ^{[2
]}

Lauria, Angelo ^{[3
]}

Pozzilli, Paolo ^{[3
,4
]}

机构：

[1] Careggi Teaching Hosp, Diabet Agcy, Florence, Italy

[2] Careggi Teaching Hosp, Obes Agcy, Florence, Italy

[3] Univ Campus Biomed, Dept Endocrinol & Diabet, Rome, Italy

[4] Univ London, Ctr Diabet, St Bartholomews & London Sch Med, London, England

来源：

DIABETES CARE | 2013年 / 36卷

关键词：

ALL-CAUSE MORTALITY; POSITION STATEMENT; RISK; EVENTS; TYPE-1; HYPERGLYCEMIA; PIOGLITAZONE; HYPOGLYCEMIA; METAANALYSIS; COMPLICATIONS;

D O I：

10.2337/dcS13-2018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：S259 / S263

页数：5

共 40 条

[1] Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control [J].

Anagnostis, P. ;

Athyros, V. G. ;

Adamidou, F. ;

Panagiotou, A. ;

Kita, M. ;

Karagiannis, A. ;

Mikhailidis, D. P. .

DIABETES OBESITY & METABOLISM, 2011, 13 (04) :302-312

[2]

[Anonymous], NEW ENGL J MED

[3]

[Anonymous], 2000, LANCET

[4] Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways [J].

Ban, Kiwon ;

Noyan-Ashraf, M. Hossein ;

Hoefer, Judith ;

Bolz, Steffen-Sebastian ;

Drucker, Daniel J. ;

Husain, Mansoor .

CIRCULATION, 2008, 117 (18) :2340-2350

[5] Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study [J].

Barr, E. L. M. ;

Boyko, E. J. ;

Zimmet, P. Z. ;

Wolfe, R. ;

Tonkin, A. M. ;

Shaw, J. E. .

DIABETOLOGIA, 2009, 52 (03) :415-424

[6] Insulin Resistance, Hyperglycemia, and Atherosclerosis [J].

Bornfeldt, Karin E. ;

Tabas, Ira .

CELL METABOLISM, 2011, 14 (05) :575-585

[7]

Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894

[8] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[9] Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes [J].

Duckworth, William ;

Abraira, Carlos ;

Moritz, Thomas ;

Reda, Domenic ;

Emanuele, Nicholas ;

Reaven, Peter D. ;

Zieve, Franklin J. ;

Marks, Jennifer ;

Davis, Stephen N. ;

Hayward, Rodney ;

Warren, Stuart R. ;

Goldman, Steven ;

McCarren, Madeline ;

Vitek, Mary Ellen ;

Henderson, William G. ;

Huang, Grant D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) :129-U62

[10] High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive [J].

Ferrannini, E. ;

Betteridge, D. J. ;

Dormandy, J. A. ;

Charbonnel, B. ;

Wilcox, R. G. ;

Spanheimer, R. ;

Erdmann, E. ;

DeFronzo, R. A. ;

Laakso, M. .

DIABETES OBESITY & METABOLISM, 2011, 13 (08) :759-764

← 1 2 3 4 →